Conditions: Chronic Rhinosinusitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 33
Healthy volunteers: no

Brief summary:
The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice daily intranasal antibiotic irrigations. The two treatments will be compared to see if there is any difference in patient outcomes. This will help guide treatment strategies for patients with CRS in the future.

Detailed description:
See brief summary.

Arms:
arm 1: Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days arm 2: Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.

Interventions: intervention 1: oral levofloxacin intervention 2: nebulized levofloxacin
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_SAP_000.pdf: 
STUDY00000407 
Version date: 03/07/2019 
 
Oral vs. Topical Antibiotic Therapy for Treatment of Chronic 
Rhinosinusitis Exacerbations 
 
Alexis M. Strohl, MD 
Steven R. Gill, PhD 
Li-Xing Man, MSc, MD, MPA 
 
Background 
Chronic Rhinosinusitis (CRS) is a common condition that affects approximately13 percent of the 
United States population annually.1 CRS is a persistent symptomatic inflammation of the nasal 
cavity and paranasal sinuses due to a variety of host and environmental factors.2 According to the 
American Academy of Otolaryngology-Head and Neck Surgery definition, the diagnosis of CRS 
requires that patients have at least 2 signs or symptoms of rhinosinusitis (mucopurulent drainage, 
nasal obstruction, facial pain, pressure, fullness, or hyposmia) for at least 12 weeks as well as 
documented inflammation on nasal endoscopy or radiographic imaging.3 Treatment is focused on 
decreasing mucosal inflammation, controlling infection, and improving mucociliary clearance.2 
Patients who are symptomatic despite medical therapy may undergo endoscopic sinus surgery 
(ESS). Given the chronic nature of the disease, CRS patients who have undergone endoscopic sinus 
surgery may continue to have intermittent, acute exacerbations of rhinosinusitis.  
There are no FDA approved treatments for acute exacerbations of chronic rhinosinusitis. The 
mainstay therapy is topical nasal steroids and culture-directed oral antibiotics.4 Recent studies 
suggest that topical antibiotics may provide a more potent and targeted therapeutic option for CRS 
exacerbations. 5-15 In post-ESS patients, the open paranasal sinuses result in improved penetration 
of topical medical therapies, making topical antibiotics an attractive treatment option.16 Available 
delivery methods include irrigation, nebulization, atomization, and spray.5-14,17 Overall there has 
been no improvement demonstrated by the use of topical antibiotic sprays, but there has been low-
level evidence to support the use of topically irrigated and nebulized antibiotic therapies with 
overall improvement in patient outcomes.4 To our knowledge, there have been no studies 
comparing nebulizations to irrigations in the treatment of chronic or acute on chronic 
rhinosinusitis, thus indicating one method of delivery is superior to another. Nebulized therapies 
have the benefit of a predictably large particle size that results in high intranasal retention.18 
Treatment is well tolerated overall with no major adverse effects reported in the literature.16 Minor 
side effects are rare and include local irritation, cough, headache, and sore throat.12,16,19 Despite 
gains in popularity, there is currently little evidence to support the efficacy of topical antibiotic 
treatments in comparison to oral antibiotics.4,17 
Antibiotic treatment of chronic rhinosinusitis is currently based on the organisms that are cultured 
from the sinonasal cavity. The most prevalent organisms cultured from patients in acute bacterial 
rhinosinusitis include Streptococcus pneumonia, Haemophilus influenza, Moraxella catarrhalis, and 
Staphylococcus aureus.20 The bacteria involved in chronic rhinosinusitis are similar, with 
Staphylococcus aureus being most prevalent, and Pseudomonas aeruginosa, Haemophillus spp, and 


STUDY00000407 
Version date: 03/07/2019 
 
Streptococcus pneumonia also contributing to the disease etiology.21 The microbial contribution to 
chronic rhinosinusitis is not limited to these pathogens. Considerable interest has been shown in 
the role of bacterial biofilms to disease. Composition of these biofilms, as well as total bacterial 
population, has been elucidated using molecular tools with the capability of identifying all bacteria 
present in a sample.22-24 These techniques have been used previously to compare the bacterial 
communities of patients with CRS to healthy patients. There have not been any previous studies 
that have compared patients with acute exacerbations of CRS pre- and post- antibiotic treatment.  
Purpose 
1. Evaluation of the efficacy of culture-directed sinonasal antibiotic nebulizations in treating 
post-endoscopic sinus surgery CRS patients with active rhinosinusitis compared to 
conventional treatment with oral antibiotics.  
2. Determination of changes in the total bacterial community of the sinonasal cavity following 
oral antibiotic therapy vs. topical antibiotic treatment. 
Methods 
Subjects 
The rhinology clinic at the University of Rochester Medical Center routinely follows CRS patients 
with nasal endoscopy and with disease-specific quality-of-life questionnaires. Our current clinical 
standard of practice includes obtaining a sinonasal culture directed by nasal endoscopy and making 
treatment decisions based on the culture results. We will recruit post-ESS CRS patients with 
worsening symptoms and mucopurulence in the paranasal sinuses seen on nasal endoscopy. Up to 
100 potential subjects meeting the defined inclusion criteria will be approached during routine 
clinic visits with a goal for enrollment of 70 patients. Enrollment is defined as entering the study 
and receiving treatment.  We will screen more patients than will be enrolled, anticipating that 
approximately 30 patients will not be eligible for inclusion based on their culture results. Patients 
will not be eligible for inclusion if they are systemically ill at the time of their initial visit or if they 
require antibiotic treatment prior to finalization of culture data. Justification for a sample size of 70 
(35 subjects per treatment group) is based on the assumptions that (1) 90% of patients taking 
culture-directed oral antibiotics will experience a clinical and statistically significant improvement 
in Rhinosinusitis Disability Index (RSDI) score at the end of therapy, and (2) The non-inferiority 
limit of topical therapy is 20% of oral therapy. Using a standard deviation of 20% and a power of 
0.9, 26 subjects will be required in each treatment group. We will enroll more subjects than 
required to compensate for any exclusions made once treatment is initiated and for subjects who 
drop out of the study. 
Male and female adults of any race will be considered for inclusion. Mentally and physically 
disabled persons will be allowed to participate if they exhibit the capacity to consent to participate 
in the research, to carry out the treatment regimen, and to accurately communicate and record 
their symptoms, which will be based on the physician’s assessment at their initial visit.  There will 
be no exclusion based on economic or educational disadvantage.  Prisoners will not be included in 
the study population due to difficulties coordinating care and administering nebulization therapy. 


STUDY00000407 
Version date: 03/07/2019 
 
 
Inclusion criteria 
1. Adults (age ≥ 18). 
2. Diagnosis of CRS. 
3. Worsening sinonasal symptoms. 
4. Previous bilateral ESS (including maxillary antrostomy and anterior ethmoidectomy). 
5. English speaking. 
6. Open sinuses (open middle meatus bilaterally; determined on endoscopy). 
7. Positive sinonasal culture (1+ or greater) with sensitivity to Levofloxacin. 
8. Individuals must have the ability to understand the requirements of the research and be able to 
provide consent to participate. 
Exclusion criteria 
1. Patients < 18 years of age.  
2. Treatment with systemic or topical antibiotics within the last 1 month. 
3. Pregnant women.  
4. Non-English speaking persons.  
5. Systemically ill at initial visit necessitating treatment prior to culture data. 
6. Allergy to Levofloxacin or other fluroquinolones 
7. Patients with a history of long Q-T syndrome.  
8. Patients currently taking medications that prolong the Q-T interval.  
9. Sinonasal culture with less than 1+ growth. 
10. Multiple organisms grown on culture that are not sensitive to a single antibiotic. 
11. Patients with ciliary function disorders (cystic fibrosis, Kartagener’s syndrome, ciliary 
dyskinesia). 
12. Patients with immunodeficiencies. 
Study Design 
Sinonasal cultures guided by nasal endoscopy via aspiration with a Tami Sinus Secretion Collector 
(Medtronic, Minneapolis, MN) will be performed. Aerobic cultures will be obtained, according to the 
clinical standard of care. If bilateral sinuses appear infected, representative cultures will be taken 
from each side. After suctioning purulent material, a sterile swab with flocked nylon fiber will be 
brushed along the mucosa in bilateral maxillary sinuses The swabs will be placed into separate 
storage buffers for transport to the laboratory for further molecular analysis. Positive cultures will 
be defined as 1+ or greater organism growth. Patients with positive cultures will be randomized to 
one of two treatment groups:  
(1) Daily oral Levofloxacin with twice daily nebulized intranasal placebo for 14 days, or  
(2) Daily oral placebo with twice daily nebulized intranasal topical Levofloxacin for 14 days.  


STUDY00000407 
Version date: 03/07/2019 
 
Each nostril will be irrigated with approximately 120 mL of saline solution prior to administration 
of the nebulized placebo or antibiotic. Patients will not be eligible for enrollment into the study if 
any organisms are not susceptible to Levofloxacin.  Additionally, if bilateral cultures are obtained, 
the patient will only be eligible for inclusion if all cultures are susceptible to Levofloxacin.  
Subjects will enter the blinding process after culture data has been reviewed. A sealed envelope 
blinded to the investigators selecting either an oral or topical antibiotic will be sent to the 
participating pharmacy (Professional Arts Pharmacy, Lafayette, LA). This will be based on a 
separate key that has been blinded to the investigators that will randomly assign a study 
participant to either an oral or topical antibiotic with the appropriate corresponding placebo. The 
list will be maintained by the study coordinator. A saline rinse kit (Sinus Rinse, NeilMed, Santa 
Rosa, CA) and isotonic salt preparation will be supplied to the patient at their initial visit. A nasal 
nebulizer (NasoNeb, Medinvent, White Bear Lake, MN) and the topical antibiotic with oral placebo 
or topical placebo with oral antibiotic will be mailed to the subject by the participating pharmacy. 
Alternatively, instead of the pharmacy shipping to the subject’s home, subjects may pick up the 
appropriately randomized medication regimen from the otolaryngology clinic at Clinton Woods, 
with the prescription then sent to the participating pharmacy (PAP) to refill the stock. The clinical 
technician at the clinic in charge of ordering and receiving will be responsible for receipt and 
storage of the study medication, under the direction and supervision of the PI. The medication will 
be stored securely in the Clinical Trials office at Clinton Woods. The study drug will be labelled as 
“Regime A” or “Regime B” corresponding to the randomization scheme in order to ensure that the 
subject receives the correct medication. The study drug will be dispersed to the subject at the clinic 
by the PI, or by medically qualified study personnel who receive the culture results (ENT attending, 
resident or mid-level provider). Patients will be contacted by telephone by study personnel 
approximately 3 days following delivery of antibiotics to ensure the medications were received and 
approximately one week later to assess compliance with twice-daily irrigations and nebulizations 
and to evaluate for any side effects the patient may be experiencing. The participating pharmacy 
will also contact the patient prior to and following the delivery of medication to instruct the patient 
on use of the nebulizer, per their current clinical standard of care.  A diary will also be given to the 
patient at their initial visit to assist with compliance.  
At the end of treatment, an otolaryngologist blinded to the treatment will repeat nasal endoscopy, 
cultures, and sinonasal brushings to assess response. If there is no mucopurulent drainage within 
the sinonasal cavity, 3 cc of normal saline will be irrigated into the maxillary sinus and sent for 
culture. Change in Rhinosinusitis Disability Index (RSDI) scores will serve as the primary outcome. 
The RSDI is a validated, rhinosinusitis-specific 30-item quality-of-life questionnaire.25 It relates the 
physical, functional, and emotional quality-of-life domains to rhinosinusitis. The survey is set up as 
an equal-appearing five point scale designated by the words “never”, “almost never”, “sometimes”, 
“almost always”, and “always”. Total scores range between 0 and 120 with high scores indicating 
greater burden of disease.  Secondary outcomes will be change in Sinonasal Outcome Test (SNOT)-
22 scores,26 change in nasal endoscopy findings using Perioperative Sinus Endoscopy (POSE) 
scores27, post-treatment culture negativity defined as less than 1+ growth of organisms, and change 
in the total bacterial community following treatment as determined by RNA pyrosequencing. The 
study participants will be routinely followed in clinic with nasal endoscopy at 2 month intervals for 


STUDY00000407 
Version date: 03/07/2019 
 
up to 6 months from the time of enrollment, or until the study is closed, to evaluate for disease 
recurrence or progression. 
 
Molecular Analysis 
For the molecular section of the study, samples will be collected via mucosal brushings and as 
detailed above in the Tami Sinus Secretion Collector. From the Collector, samples will be aseptically 
divided into two aliquots: one to the microbiology lab for conventional culturing, and one for 
molecular work. Each sample will be assigned a unique sample identification number (UID) that 
will be separated from the patient identification. This list will be administered by the study 
coordinator. Brushings and aliquots of the sample allocated to the molecular work will be 
transferred into lysis buffer for RNA pyrosequencing 28. The remainder of the sample will be frozen, 
and maintained at -80C for the remainder of the study.  
All of the collected samples of the study will be streaked for anaerobic growth in the research 
laboratory for speciation.  The primary samples will then be analyzed for total bacterial 16s rRNA, 
allowing comparison of the microbiome within and between pre- and post-treatment in both study 
arms. 
It is anticipated that there may be patients that may not respond to the antibiotic treatment in 
either the oral or topical antibiotic treatment groups. In this case, the samples that were banked at -
80C would be submitted for bacterial RNA transcriptional profiling. Additionally, the correlating 
banked nasal swab sample would be submitted for human RNA transcriptional profiling. This will 
allow comparison of the genes expressed by the bacteria that evaded antibiotic therapy in the two 
treatment arms. Similarly, it will also allow comparison of genes expressed by human endonasal 
mucosa in response to infection and therapy. Numbers of patients for this part of the study will be 
determined based on the failure of therapy rate. 
After original patient samples have been speciated, and antibiotic sensitivity has been assessed, 
cultures from the Microbiology Lab will be given the correlating deidentified UID, and frozen at -
80C to allow potential future analysis of the isolated strains. Study of these strains will be 
conducted using the deidentified UID. Samples will be kept at -80 for the remainder of the study. 
 
 
 
 
 
 


STUDY00000407 
Version date: 03/07/2019 
 
 
 
 
 Timeline 
 
Data Collection, Analysis and Monitoring 
Time (Weeks) 
Steps 
Notes 
Date of enrollment 
(Week 0) 
1. Patient questionnaire 
completed in waiting room. 
2. Patient examined with nasal 
endoscopy.  
3. Cultures obtained. 
4. Molecular analysis samples 
obtained and frozen. 
5. Consent obtained. 
6. Participant given sinus rinse 
bottle, and saline packets. 
 
 
Part of current clinical practice. 
 
 
Part of current clinical practice. 
 
 
Part of current clinical practice. 
Telephone 
call/Start of 
therapy (Day 3-7) 
1. Antibiotic, placebo and 
nebulizer mailed to subject, 
or picked up by subject at 
the clinic, depending on the 
subject’s preference. 
2. Subject instructed on use of 
nebulizer. 
3. Therapy initiated. 
 
 
Telephone call 
(Start of therapy + 
7 days) 
1.    Compliance check. 
 
Follow-up (start of 
therapy +14 days) 
1. Patient questionnaire 
completed in waiting room. 
2. Patient examined with nasal 
endoscopy.  
3. Cultures obtained 
4. Molecular analysis samples 
obtained and frozen. 
5. Therapy terminated. 
 
 
 
 
 
 
Routine follow-up 
(every 2 months) 
1. Patient questionnaire 
completed in waiting room 
2. Patient examined with nasal 
endoscopy.  
 
Part of current clinical practice. 
 
 
Part of current clinical practice. 
 


STUDY00000407 
Version date: 03/07/2019 
 
Data including patient demographics, endoscopic results, culture data, and quality of life 
questionnaire scores will be collected and stored on a password protected, encrypted share drive. 
Any printed data will be stored in the study personnel’s office in a locked file cabinet. Only the study 
personnel will have access to identifying information. Research subjects will be given a unique 
study number that is stored separately from collected data. The results will be analyzed at the 
study’s completion. A data safety monitoring plan will be ongoing and performed by the 
investigators. Any adverse events will be recorded and monitored for trends throughout the entire 
study period. Any serious adverse events will be scrutinized by the principal investigators and 
study termination will be considered if indicated. 
Risk/Benefit Assessment 
Risk Category 
This is a greater than minimal risk study since it is not necessarily routine to repeat a nasal 
endoscopy and culture following completion of antibiotic treatment, particularly if the patient is 
symptomatically improved.  
Potential Risk 
Potential risks to the subject include mild discomfort and nasal irritation secondary to nasal 
endoscopy, in addition to any added inconvenience for having to return to the clinic for re-
examination. There is a small risk of loss of privacy to the subjects. Genetic information obtained 
from human subjects will be limited to genes that are currently being expressed. 
The remainder of the study is within accordance to the current standards of clinical practice and 
will not add any additional risk to the patients. The oral and topical treatments proposed are 
generally safe without any major adverse events reported in the literature.16 There are no 
anticipated benefits for the patients participating in the study. Non-participation will not affect the 
patient’s care and they will be treated according to the current standard of care employed by the 
University of Rochester’s Rhinology clinic. 
Protection Against Risk 
Study participants will be deidentified using a unique study number. All protected health 
information will be securely stored on a password-protected, encrypted share drive. Any written 
information will be stored in a locked filing cabinet in the PI’s office and will be disposed of in a 
protected health information bin after 5 years has elapsed.  
Safety Monitoring 
The principle investigators will be responsible for safety monitoring. All adverse events related to a 
subject’s participation in the research study will be reported to the University of Rochester’s 
Research Subject Review Board (RSRB) as a summary in the annual progress report for the study.  
Serious, unexpected, and related to the study adverse events will be reported to the RSRB in a 


STUDY00000407 
Version date: 03/07/2019 
 
written report within ten calendar days of the study team being notified of the adverse event 
occurrence.  
Sample storage and confidentiality 
Collected samples will be assigned a unique sample identification number (UID) and placed into 
storage at –800 C. It will be the responsibility Dr. Gill or his designee to ensure that all samples are 
stored under appropriate conditions according to type. Samples will be stored indefinitely unless a 
subject requests, in writing, that their sample(s) be destroyed. 
A database will be developed to accompany the sample. Each case will be assigned a unique ID 
number and all identifiers will then be deleted, except for a single copy (key) containing the ID 
number, and medical record number. This database would provide clinical and pathological 
parameters and contain the following information: date of collection, initials of attending physician, 
gender, date of birth, type of antibiotic used, clinical response to therapy and final microbial 
diagnosis. It may also contain pertinent medical history and comorbidities, as well as social aspects 
of history, including tobacco use. Collection of information for the database will be the 
responsibility of Dr. Strohl. Study records will be kept in a locked filing cabinet in the Principal 
Investigator’s office in the Department of Otolaryngology at the University of Rochester or on a 
password-protected encrypted share drive. The results of any research studies performed with the 
banked samples may be presented at meetings or in publications without disclosure of subject 
identity. 
Subject Identification, Recruitment and Consent 
Study subjects meeting the defined inclusion and exclusion criteria will be recruited from the 
rhinology clinic at the University of Rochester Medical Center.  In addition, patients with a diagnosis 
of CRS that are status post bilateral sinus surgery but are not currently infected will be offered a 
flyer outlining the specifics of our study. The flyer will instruct the patients to call our research 
coordinator for a telephone screening. If eligible, they will be contacted by an investigator for an 
examination. Eligible patients will also have information about the study printed in their checkout 
materials via eRecord smartphrase, with instructions to contact Dr Man prior to taking antibiotics 
for a flare up. Similarly an eRecord smartphrase will be used to inform PCP that the patient may be 
study eligible if they present with a CRS flare up.  
Treatment options proposed are routinely used for CRS patients. This decreases the risk of any 
undue influence, as patients would be receiving one of these treatment regimens regardless of their 
inclusion in the study.  Patients electing to participate will undergo an informed consent process by 
one of the investigators. The study will be explained at length and the consent form will be 
reviewed with the patient. All questions or concerns will be addressed to the patient’s satisfaction. 
The subject will be given the option of reviewing the consent form at home if desired. The decision 
to participate or not to participate will not alter their care in any way.  
Costs 


STUDY00000407 
Version date: 03/07/2019 
 
Costs to the patients will be minimal. The initial visit, nasal endoscopy, and culture are current 
clinical standards of practice and will be billed to the patient’s insurance. The patient will not be 
charged for follow up visits, repeat cultures, medical supplies for the study, or medications 
prescribed.  
References 
1. 
Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: 
National Health Interview Survey, 2010. Vital and health statistics Series 10, Data from the 
National Health Survey 2012:1-207. 
2. 
Suh JD, Kennedy DW. Treatment options for chronic rhinosinusitis. Proceedings of the 
American Thoracic Society 2011; 8:132-140. 
3. 
Rosenfeld RM, Andes D, Bhattacharyya Net al. Clinical practice guideline: adult sinusitis. 
Otolaryngology--head and neck surgery : official journal of American Academy of 
Otolaryngology-Head and Neck Surgery 2007; 137:S1-31. 
4. 
Lim M, Citardi MJ, Leong JL. Topical antimicrobials in the management of chronic 
rhinosinusitis: a systematic review. American journal of rhinology 2008; 22:381-389. 
5. 
Solares CA, Batra PS, Hall GS, Citardi MJ. Treatment of chronic rhinosinusitis exacerbations 
due to methicillin-resistant Staphylococcus aureus with mupirocin irrigations. American 
journal of otolaryngology 2006; 27:161-165. 
6. 
Seiberling KA, Aruni W, Kim S, Scapa VI, Fletcher H, Church CA. The effect of intraoperative 
mupirocin irrigation on Staphylococcus aureus within the maxillary sinus. International 
forum of allergy & rhinology 2013; 3:94-98. 
7. 
Uren B, Psaltis A, Wormald PJ. Nasal lavage with mupirocin for the treatment of surgically 
recalcitrant chronic rhinosinusitis. The Laryngoscope 2008; 118:1677-1680. 
8. 
Moss RB, King VV. Management of sinusitis in cystic fibrosis by endoscopic surgery and 
serial antimicrobial lavage. Reduction in recurrence requiring surgery. Archives of 
otolaryngology--head & neck surgery 1995; 121:566-572. 
9. 
Neher A, Fischer H, Appenroth Eet al. Tolerability of N-chlorotaurine in chronic 
rhinosinusitis applied via yamik catheter. Auris, nasus, larynx 2005; 32:359-364. 
10. 
Moshaver A, Velazquez-Villasenor L, Lavigne F, Witterick IJ. Selective irrigation of paranasal 
sinuses in the treatment of recalcitrant chronic sinusitis. American journal of rhinology & 
allergy 2010; 24:371-373. 
11. 
Desrosiers MY, Salas-Prato M. Treatment of chronic rhinosinusitis refractory to other 
treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: 
results of a controlled trial. Otolaryngology--head and neck surgery : official journal of 
American Academy of Otolaryngology-Head and Neck Surgery 2001; 125:265-269. 
12. 
Vaughan WC, Carvalho G. Use of nebulized antibiotics for acute infections in chronic 
sinusitis. Otolaryngology--head and neck surgery : official journal of American Academy of 
Otolaryngology-Head and Neck Surgery 2002; 127:558-568. 
13. 
Kamijyo A, Matsuzaki Z, Kikushima Ket al. Fosfomycin nebulizer therapy to chronic 
sinusitis. Auris, nasus, larynx 2001; 28:227-232. 
14. 
Scheinberg PA, Otsuji A. Nebulized antibiotics for the treatment of acute exacerbations of 
chronic rhinosinusitis. Ear, nose, & throat journal 2002; 81:648-652. 
15. 
Desrosiers M, Bendouah Z, Barbeau J. Effectiveness of topical antibiotics on Staphylococcus 
aureus biofilm in vitro. American journal of rhinology 2007; 21:149-153. 
16. 
Rudmik L, Hoy M, Schlosser RJet al. Topical therapies in the management of chronic 
rhinosinusitis: an evidence-based review with recommendations. International forum of 
allergy & rhinology 2013; 3:281-298. 


STUDY00000407 
Version date: 03/07/2019 
 
17. 
Sykes DA, Wilson R, Chan KL, Mackay IS, Cole PJ. Relative importance of antibiotic and 
improved clearance in topical treatment of chronic mucopurulent rhinosinusitis. A 
controlled study. Lancet 1986; 2:359-360. 
18. 
Manes RP, Tong L, Batra PS. Prospective evaluation of aerosol delivery by a powered nasal 
nebulizer in the cadaver model. International forum of allergy & rhinology 2011; 1:366-371. 
19. 
Leonard DW, Bolger WE. Topical antibiotic therapy for recalcitrant sinusitis. The 
Laryngoscope 1999; 109:668-670. 
20. 
Payne SC, Benninger MS. Staphylococcus aureus is a major pathogen in acute bacterial 
rhinosinusitis: a meta-analysis. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 2007; 45:e121-127. 
21. 
Cleland EJ, Bassiouni A, Wormald PJ. The bacteriology of chronic rhinosinusitis and the pre-
eminence of Staphylococcus aureus in revision patients. International forum of allergy & 
rhinology 2013. 
22. 
Abreu NA, Nagalingam NA, Song Yet al. Sinus microbiome diversity depletion and 
Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Science 
translational medicine 2012; 4:151ra124. 
23. 
Feazel LM, Robertson CE, Ramakrishnan VR, Frank DN. Microbiome complexity and 
Staphylococcus aureus in chronic rhinosinusitis. The Laryngoscope 2012; 122:467-472. 
24. 
Stephenson MF, Mfuna L, Dowd SEet al. Molecular characterization of the polymicrobial 
flora in chronic rhinosinusitis. Journal of otolaryngology - head & neck surgery = Le Journal 
d'oto-rhino-laryngologie et de chirurgie cervico-faciale 2010; 39:182-187. 
25. 
Benninger MS, Senior BA. The development of the Rhinosinusitis Disability Index. Archives 
of otolaryngology--head & neck surgery 1997; 123:1175-1179. 
26. 
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item 
Sinonasal Outcome Test. Clinical otolaryngology : official journal of ENT-UK ; official journal 
of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2009; 34:447-
454. 
27. 
Wright ED, Agrawal S. Impact of perioperative systemic steroids on surgical outcomes in 
patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative 
Sinus Endoscopy (POSE) scoring system. The Laryngoscope 2007; 117:1-28. 
28. 
Zhu L, Baker SS, Gill Cet al. Characterization of gut microbiomes in nonalcoholic 
steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. 
Hepatology 2013; 57:601-609.